The function of cytoskeletal proteins in the modulation of vascular smooth muscle cell (SMC) phenotype during vascular disease is poorly understood. In this report, we used a combination of gene targeting and Cre/loxmediated cell fate mapping in mice to investigate the role of SM22␣, an SMC-specific cytoskeletal protein of unknown function, in the development of atherosclerosis. In hypercholesterolemic ApoE-deficient mice, genetic ablation of SM22␣ resulted in increased atherosclerotic lesion area and a higher proportion of proliferating SMCderived plaque cells. These results identify a role for SM22␣ in the regulation of SMC phenotype during atherogenesis.
The function of cytoskeletal proteins in the modulation of vascular smooth muscle cell (SMC) phenotype during vascular disease is poorly understood. In this report, we used a combination of gene targeting and Cre/loxmediated cell fate mapping in mice to investigate the role of SM22␣, an SMC-specific cytoskeletal protein of unknown function, in the development of atherosclerosis. In hypercholesterolemic ApoE-deficient mice, genetic ablation of SM22␣ resulted in increased atherosclerotic lesion area and a higher proportion of proliferating SMCderived plaque cells. These results identify a role for SM22␣ in the regulation of SMC phenotype during atherogenesis.
S M22␣ (also known as transgelin, WS3-10, or p27) is a 22-kDa protein that is considered a marker of contractile smooth muscle cells (SMCs) and is exclusively and abundantly expressed in SMCs of adult animals. It is structurally related to the actin-binding protein calponin and has been localized within the cytoskeletal apparatus (see review 1 ). The analysis of SM22␣-deficient mice showed that the protein is not required for the development and basal homeostatic functions of SMCs, 2 suggesting that its function can be compensated by homologous proteins like calponin and SM22␤. 3 The role of SM22␣ under pathophysiological settings such as atherosclerosis was not studied yet. A critical step in atherogenesis is the phenotypic modulation of vascular SMCs from contractile to synthetic/proliferative cells, 4 a process which may involve the cytoskeleton. 5 In this study, we have investigated the function of SM22␣ in a mouse model of atherosclerosis by using gene targeting technology combined with temporally controlled Cre/lox-mediated activation of a reporter gene to visualize the fate of SMCs during plaque development. 6, 7 
Materials and Methods
Western blot analysis, immunohistochemistry, X-Gal and Oil Red O staining, measurement of plasma lipids, and quantification of ath-erosclerotic lesion area were performed as described previously 7, 8 and in the online data supplement at http://circres.ahajournals.org.
Results and Discussion
The generation of mice carrying a SM22␣ knock-in allele, also designated SM-CreER T2 (ki), has been described. 8 The structures of the SM22␣ wild-type (ϩ) and knock-in (Ϫ) allele are depicted in Figure 1A . The knock-in allele expresses the tamoxifen-activated CreER T2 recombinase instead of the endogenous SM22␣ gene. Western blot analysis demonstrated that the SM22␣ protein was expressed in SMC-containing tissues of SM22␣ ϩ/ϩ and SM22␣ ϩ/Ϫ mice, but not in SM22␣ Ϫ/Ϫ mice ( Figure 1B ). Confirming previous results with another SM22␣-deficient mouse line, 2 the SM22␣ Ϫ/Ϫ mice generated in the present study were viable and fertile, and exhibited no obvious phenotype of SMCcontaining tissues under basal conditions (data not shown). As measured by the tail-cuff method, heart rate and mean blood pressure of SM22␣ Ϫ/Ϫ mice (644Ϯ19 bpm and 87Ϯ5 mm Hg) was not different from wild-type mice (620Ϯ24 bpm and 88Ϯ5 mm Hg). To study the role of SM22␣ in the modulation of SMC phenotype during atherogenesis, control (CTR) and SM22␣ knockout (KO) mice were generated on an ApoE-deficient 9 C57BL/6 genetic background (genotype: SM22␣ ϩ/Ϫ ; ApoE Ϫ/Ϫ and SM22␣ Ϫ/Ϫ ; ApoE Ϫ/Ϫ , respectively) and fed an atherogenic diet (20% fat, 1.5% cholesterol) for 8 or 16 weeks. The presence of the knock-in allele in both CTR and KO mice allowed us to control for potential unspecific effects related to CreER T2 expression as well as to label SMCs during atherogenesis (see later). SM22␣ was expressed in aortic SMCs of CTR mice and appeared to be downregulated in atherosclerotic lesions ( Figure 1C ), in agreement with published data. 10 Body weight and plasma lipid levels were not significantly different between CTR and KO mice (online Table 1 in the online data supplement).
The mean atherosclerotic lesion area, as determined by Oil Red O staining of the aorta, was significantly elevated in KO mice compared with CTR mice (Figures 2A through 2D) . In KO mice, the lesion area in the aortic arch (Figures 2A and  2C ) after 8 and 16 weeks on the atherogenic diet, respectively, was increased by Ϸ39% and Ϸ27% in female animals, and by Ϸ60% and Ϸ28% in male animals. Similarly, the lesion area of KO mice in the brachiocephalic artery, left carotid artery, and left subclavian artery ( Figures 2B and 2D ) after 8 and 16 weeks on the atherogenic diet, respectively, was increased by Ϸ82% and Ϸ48% in female animals, and by . Number of analyzed animals (n) is given inside each column. Note that the lesion areas of ctr (SM22␣ ϩ/Ϫ ) and wild-type (SM22␣ ϩ/ϩ ) mice were not significantly different (data not shown). E, SMC fate mapping by tamoxifen-induced recombination of the R26R allele and subsequent activation of lacZ expression. Four-week-old mice were injected with tamoxifen (1 mg tamoxifen IP for 5 consecutive days), the atherogenic diet was started at 5 weeks of age, and aortas were stained with X-Gal after 16 weeks on the diet. Panels show aortic sections (10 m) of ctr (aЈ through eЈ) and ko (fЈ through jЈ) mice at equivalent positions in the ascending aorta. Serial sections of the boxed regions in aЈ and fЈ are shown in bЈ through eЈ and gЈ through jЈ, respectively. Sections were stained with X-Gal (blue) for SMC-derived cells (aЈ through dЈ; fЈ through iЈ) and with a rabbit polyclonal antiserum to PCNA (brown) to detect proliferating cells (cЈ and hЈ) or a rat monoclonal antibody to MAC-2 (brown) to detect macrophage-like cells (dЈ and iЈ). Cell nuclei were visualized with Hoechst 33258 (eЈ and jЈ). Barsϭ100 m.
Ϸ65% and Ϸ23% in male animals. These results indicated that SM22␣ inhibits plaque growth at various stages and sites of atherogenesis in both female and male mice. The relative increase in lesion area of KO versus CTR mice was higher after 8 weeks than 16 weeks, suggesting a role for SM22␣ in the initiation of SMC phenotypic modulation.
To determine the effect of SM22␣ deficiency on the properties of plaque SMCs in vivo, the fate of SMCs during the development of atherosclerotic lesions was followed in CTR and KO mice that carried the ROSA26 Cre reporter (R26R) allele 11 (genotype: SM22␣ ϩ/Ϫ ; ApoE Ϫ/Ϫ ; R26R ϩ/Ϫ and SM22␣ Ϫ/Ϫ ; ApoE Ϫ/Ϫ ; R26R ϩ/Ϫ , respectively). The R26R allele encodes a nonfunctional lacZ gene, which is activated by Cre-mediated recombination. The activated R26R allele is inherited to all progeny cells, which allows one to follow the fate of the originally labeled cells by staining tissues with X-Gal for ␤-galactosidase activity. Both CTR and KO mice expressed the tamoxifen-dependent CreER T2 recombinase from the endogenous SM22␣ promoter ( Figure 1A) . Thus, CTR and KO mice were treated with tamoxifen to label SM22␣-expressing and SM22␣-deficient SMCs, respectively. After 16 weeks on the atherogenic diet, plaques were stained with X-Gal. Blue-stained cells in the lesions of CTR and KO mice should have been derived from SM22␣expressing and SM22␣-deficient medial SMCs, respectively. We did not detect positive X-Gal staining in the bone marrow of tamoxifen-treated mice. Thus, it is unlikely that bone marrow-derived cells contributed to the stained lesional cells. In sections of atherosclerotic plaques, blue-stained cells were detected in the media and inside the lesion. The stained plaque area was strongly increased in KO mice compared with CTR mice (Figure 2E ). Quantitative analysis of SMCderived cells (X-Gal positive) and of proliferating cells (positive for proliferating cell nuclear antigen, PCNA) revealed significant differences in plaque composition between CTR and KO mice ( Figure 2E ; online Table 2 ). In plaques from KO mice, the fraction of SMC-derived cells and of proliferating cells was increased. Proliferating SMC-derived cells accounted for 6Ϯ1% and 15Ϯ1% of total plaque cells in CTR and KO mice, respectively. Thus, the increased lesion area in KO mice can be attributed, at least in part, to a higher number of proliferative SMC-derived plaque cells. Interestingly, some of the blue-stained cells were also positive for the macrophage marker, MAC-2 ( Figure 2E ), indicating that these cells were derived by transdifferentiation of SMCs to a macrophage-like state. 12 These results suggest that SM22␣ restricts plaque growth by inhibiting the phenotypic modulation of SMCs from contractile to synthetic/proliferative cells. Although the phenotypic modulation of SMCs has been considered a key pathogenic factor in atherogenesis, it is increasingly recognized that intimal SMCs play an important role in synthesizing and maintaining the protective fibrous cap of an advanced lesion. 13, 14 Failure of this repair response leads to weakening of the cap and plaque rupture, with potentially fatal consequences. Thus, SM22␣ might restrict both plaque growth and stability making it difficult to judge whether the overall effect of this protein in atherogenesis is protective or deleterious.
Taken together, the analysis of SM22␣-deficient mice supports the concept that cytoskeleton-associated proteins play an important functional role in the phenotypic modulation of SMCs during vascular remodeling. The present study focused on the role of SM22␣ in the development and proliferation of SMC-derived plaque cells. However, SM22␣ may also regulate SMC apoptosis as well as factors that are secreted by SMCs and affect the recruitment and proliferation of other cells in the lesion. The molecular mechanism behind the effect of SM22␣ on SMC phenotype is presently unknown, but may involve the reorganization of the actin cytoskeleton. 2, 15, 16 
